



**Pfizer Inc.**  
275 North Field Drive  
Lake Forest, IL 60045

January 31, 2018

Re: **IMPORTANT PRODUCT SUPPLY INFORMATION**

North American Coral Snake Antivenin (Equine)  
NDC 0008-0423-01 (vial); 0008-0423-03 (carton)

**EXTENSION OF EXPIRATION DATING TO JANUARY 31, 2019  
LOT NO. L67530**

Dear Health Care Provider:

Pfizer, Inc. would like to provide you with updated and very important information regarding North American Coral Snake Antivenin (Equine).

Pfizer, Inc., working closely with the U.S. Food and Drug Administration (FDA), is extending the expiration date of Lot No. L67530 for an additional 12 months. Pfizer, Inc. has stability data that indicate product from Lot No. L67530 continues to be within applicable release specifications. As a result, product from Lot No. L67530 will now be deemed to expire on **January 31, 2019**.

It is imperative that you do not discard any product you have in your inventory of Lot No. L67530. Please continue to maintain this product in your inventory and keep it available for use until **January 31, 2019**.

Pfizer is carefully managing North American Coral Snake Antivenin (Equine) inventories and will supply product only to direct customers.

North American Coral Snake Antivenin (Equine) is indicated only for the treatment of envenomation caused by bites of North American coral snakes- *Micrurus* (including the eastern and Texas varieties).

Patients sensitive to North America Coral Snake Antivenin (Equine) or horse serum may develop anaphylaxis. Prior to intravenous North American Coral Snake Antivenin (Equine) administration, consider performing a proper skin test and modify therapy if indicated.

Consider the following precautions to manage hypersensitivity reactions:


- Emergency medical care (e.g., epinephrine, intravenous antihistamines, and/or albuterol) should be readily available.
- Carefully monitor patients for signs and symptoms of an acute allergic reaction (e.g. urticaria, pruritus, erythema, angioedema, bronchospasm with wheezing or cough, stridor, laryngeal edema, hypotension, tachycardia)
- Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g. rash, fever, myalgia, arthralgia).

Patients who receive a course of treatment with a foreign protein such as North American Coral Snake Antivenin (Equine) may become sensitized to it. Therefore, use caution when administering a repeat course of treatment with North American Coral Snake Antivenin (Equine) for a subsequent envenomation episode.

Please see accompanying full Prescribing Information for indications and usage, dosage and administration, and important safety information. Also, the product Prescribing Information can be accessed at [www.pfizer.com](http://www.pfizer.com).

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Sincerely,



Salomon Azoulay, M.D.  
Senior Vice President  
Pfizer Essential Health Chief Medical Office

cc: US Food and Drug Administration